Outlook to keep ECB on a dovish normalization path

Weaker data are set to trigger a downward adjustment in the ECB’s macro outlook at the Dec 13 meeting. Yet comments from ECB officials suggest that the growth narrative is still viewed as fundamentally intact. At the press conference a dovish tone is set to prevail emphasizing the contingency of the policy path.

Highlights:

  • Weaker data are set to trigger a downward adjustment in the ECB’s macro outlook at the Dec 13 meeting. Yet comments from ECB officials suggest that the growth narrative is still viewed as fundamentally intact. At the press conference a dovish tone is set to prevail emphasizing the contingency of the policy path.
  • We see the ECB ending QE in December and leaving rates constant at least throughout summer 2019. However, given the latest data and higher risks, we now look for a first deposit rate hike only in December 2019.
  • We look for the announcement of an APP reinvestment period of three years to keep the term premium down but a tilt towards longer dated bonds (“operation twist”) will be hard to engineer. When outlining the details of its reinvestment policy, the ECB may hint at some flexibility in shifting from government to corporate bonds.
  • We do not expect a new TLTRO announcement as it would water down the normalization. But the ECB will not close the door; the mid-2019 cliff effect will need to be addressed if financial conditions or the economy deteriorate further.

Read the full publication below.

OUTLOOK TO KEEP ECB ON A DOVISH NORMALIZATION PATH

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.